臨床研究等提出・公開システム

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation (SERENA-6)

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

Hibi Kazusihge

Astrazeneka K.K

3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka

RD-clinical-information-Japan@astrazeneca.com

Hibi Kazushige

Astrazeneka K.K

3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka

+81-6-4802-3533

RD-clinical-information-Japan@astrazeneca.com

Not Recruiting

July. 01, 2021

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:

- Have advanced breast cancer that is not able to be treated with surgery or radiation;

- Have an ESR1 mutation in their cancer;

- Have breast cancer that is HR-positive and HER2-negative;

- Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;

- Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;

- Are able to do their daily activities;

- Are at least 18.

Full list of inclusion criteria:

- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent.

- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results.

- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib or abemaciclib) +- LHRH as the initial endocrine based treatment for advanced disease.

- Eastern Cooperative Oncology Group performance status of 0 or 1.

- ESR1m detected by central testing of ctDNA with Guardant360 CDx;

- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

- Adequate organ and marrow function

INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:

- Had certain types of tumors in the past that may come back;

- Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;

- Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.

Full list of exclusion criteria:

- Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term.

- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease.

- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

- Patient with known or family history of severe heart disease

- Previous treatment with AZD9833, investigational SERDs or fulvestrant.

- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding.

- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.

Both

ER-Positive HER2-Negative Breast Cancer

AZD9833: 75 mg, PO, once daily
AZD9833 placebo: PO, once daily
Palbociclib: PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment
Abemaciclib:150mg, PO, twice daily
Anastrozole: 1 mg, PO, once daily
Anastrozole placebo: PO, once daily
Letrozole: 2.5 mg, PO, once daily
Letrozole placebo: PO, once daily
LHRH agonist: SC, once monthly

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) [ Time Frame: From randomization until the earlier of the progression event or death (approximately 2 years) ]
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death.

+81-11-811-9111

July. 15, 2021

No

South Korea/Taiwan/Turkey/Australia/Canada/United States/Bulgaria/Hungary/Poland/Portugal/Russia/France/Germany/Austria/Switzerland/Italy/Spain/United Kingdom/Belgium/Norway/Slovakia/Israel